Kuhn Wilfried, Karp Georg, Müller Thomas
Department of Neurology, Leopoldina Hospital Schweinfurt, Schweinfurt, 97422, Germany.
Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Berlin, 13088, Germany.
Degener Neurol Neuromuscul Dis. 2022 Sep 26;12:127-131. doi: 10.2147/DNND.S362511. eCollection 2022.
Previous trials describe a decrease of vitamin D levels in patients with Parkinson's disease and relationships to clinical disease severity. This case control study found higher but not significant 25-OH-vitamin D plasma levels in patients with Parkinson's disease compared with age- and sex-matched controls and no associations to clinical parameters, such as rating scores of disease severity or assessments of cognitive function. A certain variability of vitamin D concentrations was observed in both cohorts, which were investigated during the same season. These outcomes put into perspective the emerging discussion on the importance of vitamin D in Parkinson's disease. Our results warrant further confirmatory research with a strict matching design of patients and controls, which has not been done in previous investigations. We stress that this case control study does not allow any comment on the putative beneficial effects of vitamin D supplementation, ie, on bone mass or bone mineral density, in patients with Parkinson's disease.
先前的试验描述了帕金森病患者维生素D水平的下降以及与临床疾病严重程度的关系。这项病例对照研究发现，与年龄和性别匹配的对照组相比，帕金森病患者血浆25-羟基维生素D水平较高，但无统计学意义，且与临床参数无关，如疾病严重程度评分或认知功能评估。在同一季节对两组人群进行了调查，观察到两组人群的维生素D浓度均存在一定变异性。这些结果使关于维生素D在帕金森病中的重要性的新讨论更具合理性。我们的结果需要通过对患者和对照组进行严格匹配设计的进一步验证性研究来证实，而之前的研究尚未做到这一点。我们强调，这项病例对照研究无法对补充维生素D对帕金森病患者的假定有益作用（即对骨量或骨矿物质密度的作用）发表任何评论。
